InMed Pharmaceuticals, Inc. (INM)
0.73
+0.01
(+1.39%)
USD |
NASDAQ |
May 01, 16:00
0.73
0.00 (0.00%)
After-Hours: 20:00
InMed Pharmaceuticals Enterprise Value : -4.364M for April 30, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals, Inc. | 1.723B |
| Edesa Biotech, Inc. | 149.55M |
| Lexaria Bioscience Corp. | 10.77M |
| Sirona Biochem Corp. | -- |
| Xenon Pharmaceuticals, Inc. | 4.807B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.028M |
| Revenue (Quarterly) | 0.8202M |
| Total Expenses (Quarterly) | 2.848M |
| EPS Diluted (Quarterly) | -0.5129 |
| Gross Profit Margin (Quarterly) | 3.19% |
| Profit Margin (Quarterly) | -247.3% |
| Earnings Yield | -517.5% |
| Normalized Earnings Yield | -517.53 |